Liquid Biopsies: The Future of Brain Tumor Diagnosis?
"Discover how liquid biopsies are revolutionizing brain tumor diagnosis and treatment monitoring, offering a less invasive approach with potentially greater insights."
The standard methods for monitoring and diagnosing central nervous system tumors may soon be revolutionized by minimally invasive techniques. A promising method for establishing diagnoses and tracking treatment response is the liquid biopsy, which involves sampling blood or cerebrospinal fluid.
The traditional method of evaluating how tumors respond to treatment depends heavily on neuroimaging. However, it can be challenging to correlate therapeutic response with imaging results because the intervention could impact the imaging characteristics of the tumor. For example, chemoradiation may result in increased contrast enhancement, a phenomenon known as pseudoprogression, which indicates changes to the local blood-brain barrier or radiation necrosis. Conversely, antiangiogenic drugs can alter the permeability of tumor vasculature and reduce contrast enhancement without actually reducing the disease burden.
Liquid biopsies are especially interesting for glioblastoma (GBM) tumors for a few compelling reasons. Unlike many other tumors, the biopsy procedure carries a significant amount of risk. There may be substantial brain swelling in and around the tumor, for instance. Even a small amount of hemorrhage along the biopsy tract could endanger the patient's neurological function or even their life. In addition, brain biopsies are extremely difficult when it comes to obtaining longitudinal samples or prospectively collecting tissue samples repeatedly because of the risk involved with the biopsy itself. It is more difficult to track treatment response, observe clonal evolution to find new susceptibilities or acquired mechanisms of resistance to therapy, and distinguish tumor recurrence from pseudoprogression when longitudinal samples are difficult to obtain.
Current Burden and Clinical Promise
Pediatric brain tumors are the most common solid malignancies in children, with an incidence of 5.61 per 100,000 in the United States. Current diagnostic approaches, including clinical evaluation, MRI, and tissue biopsy, face challenges such as pseudoprogression, tumor heterogeneity, surgical inaccessibility, and procedural risk. Reviews describe liquid-biopsy assays being investigated for diagnosis, tumor subtyping, relapse prediction, and prognosis monitoring. The global liquid biopsy for brain tumors market reached USD 445.2 million in 2024, according to one market report.
From Blood Tests to Brain Tumor Sampling
Liquid biopsy developed as a molecular-diagnostics approach using materials released into body fluids. Circulating tumor DNA can reveal genomic characteristics, while circulating tumor cells can reflect the risk of tumor metastasis. The term liquid biopsy became strongly associated with blood and circulating biomarkers, although research has also examined immune cells, circulating endothelial cells, and cancer-associated fibroblasts. By May 2025, reviews highlighted cerebrospinal fluid as a liquid-biopsy medium for brain cancer, extending the field beyond blood-based assays.
How Do Liquid Biopsies Work in Brain Tumors?
Liquid biopsies analyze circulating tumor cells (CTCs), cell-free nucleic acids, and extracellular vesicles (EVs). These components, found in blood or cerebrospinal fluid, offer insights into the tumor's characteristics without invasive procedures.
- Circulating Tumor Cells (CTCs): These cells, shed from the primary tumor, can reveal genetic mutations and expression patterns, offering a snapshot of the tumor's characteristics.
- Cell-Free Tumor DNA (ctDNA): Analyzing ctDNA can identify tumor-specific mutations and track the tumor's evolution over time. However, technical challenges exist due to the low concentration of nucleic acid in biofluids.
- Extracellular Vesicles (EVs): EVs, including exosomes, transport RNA, DNA, and proteins, providing a comprehensive view of the tumor's molecular profile.
Fragmentome-Based Detection
A genome-wide cell-free DNA fragmentome study used machine-learning analyses to detect brain cancer across all-grade gliomas. The method achieved an area under the curve of 0.90, with a 95% confidence interval of 0.87-0.93. These findings were validated in an independent prospectively collected cohort. The reported fragmentome changes reflected contributions from glioma cells and altered white blood cell populations in circulation.
Validation and Detection Gaps
Liquid-biopsy testing for brain cancer still requires validation in larger studies that follow people over time and evaluate performance in real-world settings. Research on cerebrospinal-fluid ctDNA found a low rate of mutation capture in glioblastoma patients, indicating that detection methods require further optimization. These limitations temper claims that liquid biopsy is ready to replace established diagnostic approaches. The available evidence therefore supports continued investigation rather than routine clinical reliance.
Blood, CSF, and Biomarker Options
Detection of ctDNA in blood remains challenging for patients with primary brain tumors. Sequencing ctDNA from cerebrospinal fluid may offer an alternative route to glioma genotyping with lower morbidity and cost than tissue-based approaches, according to one Nature study. Reviews describe brain-tumor liquid biopsy markers that include circulating tumor cells, circulating tumor DNA, microRNAs, proteins, and exosomes. Other research has specifically evaluated the diagnostic value of cerebrospinal-fluid biopsy for brain parenchymal metastases and leptomeningeal metastasis.
The Future of Liquid Biopsies
Liquid biopsies represent a significant advancement in brain tumor diagnostics, offering a non-invasive method to monitor disease progression and treatment response. As technology advances, these techniques promise to become more refined, providing clinicians with valuable insights for personalized treatment strategies. Future research will focus on improving signal detection, standardizing procedures, and integrating multi-omic data to enhance the accuracy and clinical utility of liquid biopsies. Despite existing challenges, liquid biopsies hold immense potential for transforming brain tumor care, improving patient outcomes through more precise and adaptive treatment approaches.
Toward Clinical Integration
Future liquid-biopsy research is classifying and refining detection strategies for circulating tumor DNA, circulating tumor cells, extracellular vesicles, non-coding RNAs, tumor-educated platelets, and tumor-associated antigens. A 2022 review of brain-tumor liquid biopsies called for multicenter prospective trials and collaboration among researchers. These efforts are intended to establish liquid-biopsy strategies that can produce better outcomes for patients with brain tumors. The field's next step is therefore coordinated clinical validation across institutions.
Barriers Behind the Promise
Liquid biopsy could enable noninvasive, real-time monitoring of glioblastoma through cell-free DNA, circulating tumor cells, and extracellular vesicles. However, the blood-brain barrier and low biomarker abundance remain key challenges in glioblastoma multiforme. Reviews of primary brain tumors describe two decades of promising results accompanied by continuing disappointment as well as hope. This tension reflects the gap between the biological promise of minimally invasive, personalized analysis and the difficulty of translating it into dependable clinical practice.